Search research articles
Contact Us
Filters
Showing results (101-110 of 135) with videos related to
Page
of 14
Sort By:
European Urology
|
March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Cancer
|
July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
European Urology Oncology
|
May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
Kim N Chi, Elena Castro, Gert Attard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Michael B Atkins, Brian I Rini, Robert J Motzer, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
British Journal of Cancer
|
December 21, 2025
High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD)
Visalini Nair-Shalliker, David P Smith, Val Gebski, et al.
The Lancet. Oncology
|
September 2, 2022
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles, Piotr Tomczak, Se Hoon Park, et al.
European Urology
|
September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
BJU International
|
November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
Ciara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 135) with videos related to
Sort By:
Page
of 14
European Urology
|
March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Cancer
|
July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
European Urology Oncology
|
May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
Kim N Chi, Elena Castro, Gert Attard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Michael B Atkins, Brian I Rini, Robert J Motzer, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
British Journal of Cancer
|
December 21, 2025
High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD)
Visalini Nair-Shalliker, David P Smith, Val Gebski, et al.
The Lancet. Oncology
|
September 2, 2022
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles, Piotr Tomczak, Se Hoon Park, et al.
European Urology
|
September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
BJU International
|
November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
Ciara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Page
of 14